Exhibit 99.1

                  MediCor Ltd. Reports First Quarter Earnings
                      and Announces Strong Revenue Growth

    LAS VEGAS--(BUSINESS WIRE)--Nov. 16, 2004--MediCor Ltd.
(OTCBB:MDCR) announced today its financial results for its first
fiscal quarter ending Sept. 30, 2004.
    Sales for the first quarter of fiscal year 2005 were $6,143,059,
an increase of 1,726% or $5,806,719 as compared to sales reported in
the first quarter of fiscal year 2004. The significantly higher sales
were driven by the acquisition of Eurosilicone SAS, which was
completed on July 5, 2004.
    On a pro forma basis, sales for the quarter ending Sept. 30, 2004,
increased about 30% or approximately $1.4 million over the comparable
prior year quarter. Pro forma results are shown because MediCor's
results include the substantial benefit from the acquisition of
Eurosilicone, which was not part of MediCor's results in the prior
year quarter.
    According to MediCor Chief Executive Officer Theodore R. Maloney,
"While we are certainly pleased with first quarter 2005 results, we
view them as illustrative of our larger global strategy to rapidly
grow the business through the acquisition of companies and
technologies that offer both significant market share growth potential
and sustainable profitability for our shareholders. The Eurosilicone
acquisition is the first in what we believe will be a series of
strategic milestone announcements in the near future."
    MediCor Chief Financial Officer Thomas R. Moyes added, "The
results mark the first full quarter of combined operations of
Eurosilicone and MediCor. Eurosilicone has approximately 17% of the
breast implant market outside the United States, where it competes
predominantly with Inamed Corp. (NASDAQ: IMDC) and Mentor Corp. (NYSE:
MNT). We believe these results place MediCor in the position of the
world's third largest manufacturer and distributor of breast implants
worldwide."

    About MediCor

    MediCor acquires, develops, manufactures and markets products for
medical specialties in aesthetic, plastic and reconstructive surgery
and dermatology markets. Its products are sold worldwide to hospitals,
surgery centers and physicians through primarily distributors and some
direct sales personnel. MediCor's objective is to be a leading
supplier of selected international medical devices and technologies.
To achieve this strategy, MediCor intends to build upon and expand its
business lines, primarily in the aesthetic, plastic and reconstructive
surgery and dermatology markets. MediCor intends to accomplish this
growth through the expansion of existing product lines and offerings
and through the acquisition of companies and other assets, including
intellectual property rights and distribution rights.

    About Eurosilicone

    Eurosilicone, a wholly owned subsidiary of MediCor Ltd., develops,
manufactures and markets a full range of breast implants for the
aesthetic, plastic and reconstructive surgery markets, including
silicone gel and inflatable saline-filled breast implants, with both
round and anatomical shapes, and smooth or unique micro-textured
surfaces. Eurosilicone also markets a line of external breast
prostheses under the Maxima brand sold by its Europrotex division,
available in six different shapes and a wide range of sizes.
Eurosilicone also manufactures and markets a range of other silicone
implants, including tissue expanders, testicular implants, gluteus
implants, calf implants, nasal implants, malar implants and chin
implants.

    Forward-Looking Statements

    Statements in this press release may involve forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including forward-looking statements regarding
MediCor's future credit availability and growth plans. Such statements
are based upon the current beliefs and expectations of MediCor's
management and are subject to significant risks and uncertainties,
including but not limited to external factors such as: clinical
trials, government regulation, agreements with third-party
manufacturers, product liability or other legal factors, capital
markets and the ability to obtain additional financing, economic
factors and changes in customer spending, and other factors over many
of which management has no control. These forward-looking statements
should be evaluated together with additional information about
MediCor's business, markets, conditions and other risks and
uncertainties, which could affect MediCor's future performance, which
are contained in MediCor's Annual Report on Form 10-KSB for the year
ended June 30, 2004, and its other filings with the Securities and
Exchange Commission and available at the Securities and Exchange
commission's Internet site (http://www.sec.gov), which are
incorporated into this press release by reference. Actual results may
vary materially because of risks and uncertainties. This press release
speaks only as of its date, and MediCor disclaims any duty to update
the information herein.



    CONTACT: MediCor, Las Vegas
             Marc S. Sperberg, 702-932-4560, ext. 308